B&D White Capital Company’s Moderna MRNA Stock Holding History

B&D White Capital Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-600	Closed	-$108K	–	85
2022 Q4	$108K	Buy	+600	New	+$98.1K	0.03%	89

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

B&D White Capital Company's MRNA Position: Q1 2023 in Review

B&D White Capital Company sold out of Moderna (MRNA) in Q1 2023, closing a stake of 600 shares — an estimated $108K sold.

B&D White Capital Company first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $108K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

B&D White Capital Company reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
B&D White Capital Company sold 600 Moderna shares in Q1 2023, an estimated $108K.
B&D White Capital Company first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
B&D White Capital Company's Moderna position peaked at $108K in Q4 2022.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on B&D White Capital Company's 13F filing for Q1 2023, filed 3 May 2023.